Applications of multiple reaction monitoring targeted proteomics assays in human plasma

References

• Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002;1(11):845–867.
   PubMed Web of Science ®Google Scholar
• Tuck MK, Chan DW, Chia D, et al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res. 2009;8(1):113–117.
   PubMed Web of Science ®Google Scholar
• Lim MD. Dried blood spots for global health diagnostics and surveillance: opportunities and challenges. Am J Trop Med Hyg. 2018;99(2):256–265.
   PubMed Web of Science ®Google Scholar
• Di Venere M, Viglio S, Cagnone M, et al. Advances in the analysis of “less-conventional” human body fluids: an overview of the CE- and HPLC-MS applications in the years 2015–2017. Electrophoresis. 2018;39(1):160–178.
   PubMed Web of Science ®Google Scholar
• Siwy J, Schanstra JP, Argiles A, et al. Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. Nephrol Dial Transplant. 2014;29(8):1563–1570.
   PubMed Web of Science ®Google Scholar
• Ebhardt HA, Root A, Sander C, et al. Applications of targeted proteomics in systems biology and translational medicine. Proteomics. 2015;15(18):3193–3208.
   PubMed Web of Science ®Google Scholar
• Mermelekas G, Vlahou A, Zoidakis J. SRM/MRM targeted proteomics as a tool for biomarker validation and absolute quantification in human urine. Expert Rev Mol Diagn. 2015;15(11):1441–1454.
   PubMed Web of Science ®Google Scholar
• Coelho Graca D, Hartmer R, Jabs W, et al. Detection of proteoforms using top-down mass spectrometry and diagnostic ions. Methods Mol Biol. 2019;1959:173–183.
   PubMedGoogle Scholar
• Zhao Y, Brasier AR. Qualification and verification of protein biomarker candidates. Adv Exp Med Biol. 2016;919:493–514.
   PubMed Web of Science ®Google Scholar
• Bioanalytical method validation guidance for industry: US department of health and human services, food and drug administration; 2018. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm070107.pdf,accessed on April 2019.
   Google Scholar
• Guideline on bioanalytical method validation: European Medicines Agency (EMA); 2011. Available from: https://www.ema.europa.eu/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf, accessed on April 2019.
   Google Scholar
• Kontostathi G, Makridakis M, Bitsika V, et al. Development and validation of Multiple Reaction Monitoring (MRM) assays for clinical applications. Methods Mol Biol. 2019;1959:205–223.
   PubMedGoogle Scholar
• Percy AJ, Chambers AG, Parker CE, et al. Absolute quantitation of proteins in human blood by multiplexed multiple reaction monitoring mass spectrometry. Methods Mol Biol. 2013;1000:167–189.
   PubMedGoogle Scholar
• Percy AJ, Mohammed Y, Yang J, et al. A standardized kit for automated quantitative assessment of candidate protein biomarkers in human plasma. Bioanalysis. 2015;7(23):2991–3004.
   PubMed Web of Science ®Google Scholar
• Gerber SA, Rush J, Stemman O, et al. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc Natl Acad Sci U S A. 2003;100(12):6940–6945.
   PubMed Web of Science ®Google Scholar
• Chahrour O, Cobice D, Malone J. Stable isotope labelling methods in mass spectrometry-based quantitative proteomics. J Pharm Biomed Anal. 2015;113:2–20.
   PubMed Web of Science ®Google Scholar
• Eshghi A, Borchers CH. Multiple reaction monitoring using double isotopologue peptide standards for protein quantification. Methods Mol Biol. 2018;1788:193–214.
   PubMedGoogle Scholar
• LeBlanc A, Michaud SA, Percy AJ, et al. Multiplexed MRM-based protein quantitation using two different stable isotope-labeled peptide isotopologues for calibration. J Proteome Res. 2017;16(7):2527–2536.
   PubMed Web of Science ®Google Scholar
• Wang X, Qin W, Lin H, et al. Metal-tag labeling coupled with multiple reaction monitoring-mass spectrometry for absolute quantitation of proteins. Analyst. 2013;138(18):5309–5317.
   PubMed Web of Science ®Google Scholar
• Bronsema KJ, Bischoff R van de Merbel NC. Internal standards in the quantitative determination of protein biopharmaceuticals using liquid chromatography coupled to mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;893–894:1–14.
   PubMed Web of Science ®Google Scholar
• Brun V, Dupuis A, Adrait A, et al. Isotope-labeled protein standards: toward absolute quantitative proteomics. Mol Cell Proteomics. 2007;6(12):2139–2149.
   PubMed Web of Science ®Google Scholar
• Carr SA, Abbatiello SE, Ackermann BL, et al. Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics. 2014;13(3):907–917.
   PubMed Web of Science ®Google Scholar
• Meyer JG, Schilling B. Clinical applications of quantitative proteomics using targeted and untargeted data-independent acquisition techniques. Expert Rev Proteomics. 2017;14(5):419–429.
   PubMed Web of Science ®Google Scholar
• Vidova V, Spacil Z. A review on mass spectrometry-based quantitative proteomics: targeted and data independent acquisition. Anal Chim Acta. 2017;964:7–23.
   PubMed Web of Science ®Google Scholar
• Percy AJ, Simon R, Chambers AG, et al. Enhanced sensitivity and multiplexing with 2D LC/MRM-MS and labeled standards for deeper and more comprehensive protein quantitation. J Proteomics. 2014;106:113–124.
   PubMed Web of Science ®Google Scholar
• Richard VR, Domanski D, Percy AJ, et al. An online 2D-reversed-phase - Reversed-phase chromatographic method for sensitive and robust plasma protein quantitation. J Proteomics. 2017;168:28–36.
   PubMed Web of Science ®Google Scholar
• Schmidlin T, Garrigues L, Lane CS, et al. Assessment of SRM, MRM(3), and DIA for the targeted analysis of phosphorylation dynamics in non-small cell lung cancer. Proteomics. 2016;16(15–16):2193–2205.
   PubMed Web of Science ®Google Scholar
• Percy AJ, Yang J, Chambers AG, et al. Multiplexed MRM with internal standards for cerebrospinal fluid candidate protein biomarker quantitation. J Proteome Res. 2014;13(8):3733–3747.
   PubMed Web of Science ®Google Scholar
• Gallien S, Domon B. Advances in high-resolution quantitative proteomics: implications for clinical applications. Expert Rev Proteomics. 2015;12(5):489–498.
   PubMed Web of Science ®Google Scholar
• Bourmaud A, Gallien S, Domon B. Parallel reaction monitoring using quadrupole-orbitrap mass spectrometer: principle and applications. Proteomics. 2016;16(15–16):2146–2159.
   PubMed Web of Science ®Google Scholar
• Percy AJ, Yang J, Chambers AG, et al. Protocol for standardizing high-to-moderate abundance protein biomarker assessments through an MRM-with-standard-peptides quantitative approach. Adv Exp Med Biol. 2016;919:515–530.
   PubMed Web of Science ®Google Scholar
• Percy AJ, Chambers AG, Yang J, et al. Multiplexed MRM-based quantitation of candidate cancer biomarker proteins in undepleted and non-enriched human plasma. Proteomics. 2013;13(14):2202–2215.
   PubMed Web of Science ®Google Scholar
• Burgess MW, Keshishian H, Mani DR, et al. Simplified and efficient quantification of low-abundance proteins at very high multiplex via targeted mass spectrometry. Mol Cell Proteomics. 2014;13(4):1137–1149.
   PubMed Web of Science ®Google Scholar
• Ponomarenko EA, Kopylov AT, Lisitsa AV, et al. Chromosome 18 transcriptoproteome of liver tissue and HepG2 cells and targeted proteome mapping in depleted plasma: update 2013. J Proteome Res. 2014;13(1):183–190.
   PubMed Web of Science ®Google Scholar
• Sano S, Tagami S, Hashimoto Y, et al. Absolute quantitation of low abundance plasma APL1beta peptides at sub-fmol/mL level by SRM/MRM without immunoaffinity enrichment. J Proteome Res. 2014;13(2):1012–1020.
   PubMed Web of Science ®Google Scholar
• Such-Sanmartin G, Bache N, Callesen AK, et al. Targeted mass spectrometry analysis of the proteins IGF1, IGF2, IBP2, IBP3 and A2GL by blood protein precipitation. J Proteomics. 2015;113:29–37.
   PubMed Web of Science ®Google Scholar
• Such-Sanmartin G, Ventura-Espejo E, Jensen ON. Depletion of abundant plasma proteins by poly(N-isopropylacrylamide-acrylic acid) hydrogel particles. Anal Chem. 2014;86(3):1543–1550.
   PubMed Web of Science ®Google Scholar
• Zgoda VG, Kopylov AT, Tikhonova OV, et al. Chromosome 18 transcriptome profiling and targeted proteome mapping in depleted plasma, liver tissue and HepG2 cells. J Proteome Res. 2013;12(1):123–134.
   PubMed Web of Science ®Google Scholar
• Razavi M, Leigh Anderson N, Pope ME, et al. High precision quantification of human plasma proteins using the automated SISCAPA Immuno-MS workflow. N Biotechnol. 2016;33(5 Pt A):494–502.
   PubMed Web of Science ®Google Scholar
• De Marchi T, Kuhn E, Carr SA, et al. Antibody-based capture of target peptides in multiple reaction monitoring experiments. Methods Mol Biol. 2015;1293:123–135.
   PubMedGoogle Scholar
• Krastins B, Prakash A, Sarracino DA, et al. Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum. Clin Biochem. 2013;46(6):399–410.
   PubMed Web of Science ®Google Scholar
• Gauthier MS, Perusse JR, Awan Z, et al. A semi-automated mass spectrometric immunoassay coupled to selected reaction monitoring (MSIA-SRM) reveals novel relationships between circulating PCSK9 and metabolic phenotypes in patient cohorts. Methods. 2015;81:66–73.
   PubMed Web of Science ®Google Scholar
• Hong Q, Ruhaak LR, Stroble C, et al. A method for comprehensive glycosite-mapping and direct quantitation of serum glycoproteins. J Proteome Res. 2015;14(12):5179–5192.
   PubMed Web of Science ®Google Scholar
• Huttenhain R, Surinova S, Ossola R, et al. N-glycoprotein SRMAtlas: a resource of mass spectrometric assays for N-glycosites enabling consistent and multiplexed protein quantification for clinical applications. Mol Cell Proteomics. 2013;12(4):1005–1016.
   PubMed Web of Science ®Google Scholar
• Kailemia MJ, Wei W, Nguyen K, et al. Targeted measurements of O- and N-glycopeptides show that proteins in high density lipoprotein particles are enriched with specific glycosylation compared to plasma. J Proteome Res. 2018;17(2):834–845.
   PubMed Web of Science ®Google Scholar
• Zawadzka AM, Schilling B, Held JM, et al. Variation and quantification among a target set of phosphopeptides in human plasma by multiple reaction monitoring and SWATH-MS2 data-independent acquisition. Electrophoresis. 2014;35(24):3487–3497.
   PubMed Web of Science ®Google Scholar
• Kiseleva OI, Romashova YA, Moskaleva NE, et al. Plasma preparation to measure FDA-approved protein markers by selected reaction monitoring. Clin Transl Med. 2015;4(1):32.
   PubMedGoogle Scholar
• Pechlaner R, Tsimikas S, Yin X, et al. Very-low-density lipoprotein-associated apolipoproteins predict cardiovascular events and are lowered by inhibition of APOC-III. J Am Coll Cardiol. 2017;69(7):789–800.
   PubMed Web of Science ®Google Scholar
• Percy AJ, Chambers AG, Smith DS, et al. Standardized protocols for quality control of MRM-based plasma proteomic workflows. J Proteome Res. 2013;12(1):222–233.
   PubMed Web of Science ®Google Scholar
• Percy AJ, Chambers AG, Yang J, et al. Method and platform standardization in MRM-based quantitative plasma proteomics. J Proteomics. 2013;95:66–76.
   PubMed Web of Science ®Google Scholar
• Zhu M, Zhang P, Geng-Spyropoulos M, et al. A robotic protocol for high-throughput processing of samples for selected reaction monitoring assays. Proteomics. 2017;17(6):1600339.
   Web of Science ®Google Scholar
• Fu Q, Kowalski MP, Mastali M, et al. Highly reproducible automated proteomics sample preparation workflow for quantitative mass spectrometry. J Proteome Res. 2018;17(1):420–428.
   PubMed Web of Science ®Google Scholar
• Mohammed Y, Percy AJ, Chambers AG, et al. Qualis-SIS: automated standard curve generation and quality assessment for multiplexed targeted quantitative proteomic experiments with labeled standards. J Proteome Res. 2015;14(2):1137–1146.
   PubMed Web of Science ®Google Scholar
• Abbatiello S, Ackermann BL, Borchers C, et al. New guidelines for publication of manuscripts describing development and application of targeted mass spectrometry measurements of peptides and proteins. Mol Cell Proteomics. 2017;16(3):327–328.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Park J, Choi Y, Namkung J, et al. Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel. Oncotarget. 2017;8(54):93117–93130.
   PubMedGoogle Scholar
• Kim Y, Kang M, Han D, et al. Biomarker development for intraductal papillary mucinous neoplasms using multiple reaction monitoring mass spectrometry. J Proteome Res. 2016;15(1):100–113.
   PubMed Web of Science ®Google Scholar
• Yoneyama T, Ohtsuki S, Honda K, et al. Identification of IGFBP2 and IGFBP3 as compensatory biomarkers for CA19-9 in early-stage pancreatic cancer using a combination of antibody-based and LC-MS/MS-based proteomics. PLoS One. 2016;11(8):e0161009.
   PubMed Web of Science ®Google Scholar
• Yoneyama T, Ohtsuki S, Ono M, et al. Quantitative targeted absolute proteomics-based large-scale quantification of proline-hydroxylated alpha-fibrinogen in plasma for pancreatic cancer diagnosis. J Proteome Res. 2013;12(2):753–762.
   PubMed Web of Science ®Google Scholar
• You J, Kao A, Dillon R, et al. A large-scale and robust dynamic MRM study of colorectal cancer biomarkers. J Proteomics. 2018;187:80–92.
   PubMed Web of Science ®Google Scholar
• Jones JJ, Wilcox BE, Benz RW, et al. A plasma-based protein marker panel for colorectal cancer detection identified by multiplex targeted mass spectrometry. Clin Colorectal Cancer. 2016;15(2):186–194 e13.
   PubMed Web of Science ®Google Scholar
• Lin D, Alborn WE, Slebos RJ, et al. Comparison of protein immunoprecipitation-multiple reaction monitoring with ELISA for assay of biomarker candidates in plasma. J Proteome Res. 2013;12(12):5996–6003.
   PubMed Web of Science ®Google Scholar
• Ahn YH, Shin PM, Kim YS, et al. Quantitative analysis of aberrant protein glycosylation in liver cancer plasma by AAL-enrichment and MRM mass spectrometry. Analyst. 2013;138(21):6454–6462.
   PubMed Web of Science ®Google Scholar
• Lee JY, Kim JY, Cheon MH, et al. MRM validation of targeted nonglycosylated peptides from N-glycoprotein biomarkers using direct trypsin digestion of undepleted human plasma. J Proteomics. 2014;98:206–217.
   PubMed Web of Science ®Google Scholar
• Kim D, Li AA, Gadiparthi C, et al. Changing trends in etiology-based annual mortality from chronic liver disease, from 2007 through 2016. Gastroenterology. 2018;155(4):1154–1163 e3.
   PubMed Web of Science ®Google Scholar
• Yuan W, Sanda M, Wu J, et al. Quantitative analysis of immunoglobulin subclasses and subclass specific glycosylation by LC-MS-MRM in liver disease. J Proteomics. 2015;116:24–33.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Sertamo K, Pierrard MA, et al. Verification of the biomarker candidates for non-small-cell lung cancer using a targeted proteomics approach. J Proteome Res. 2015;14(3):1412–1419.
   PubMed Web of Science ®Google Scholar
• Li XJ, Hayward C, Fong PY, et al. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci Transl Med. 2013;5(207):207ra142.
   PubMed Web of Science ®Google Scholar
• Ahn YH, Ji ES, Oh NR, et al. Differential proteomic approach for identification and verification of aberrantly glycosylated proteins in adenocarcinoma lung cancer (ADLC) plasmas by lectin-capturing and targeted mass spectrometry. J Proteomics. 2014;106:221–229.
   PubMed Web of Science ®Google Scholar
• Wu HY, Goan YG, Chang YH, et al. Qualification and verification of serological biomarker candidates for lung adenocarcinoma by targeted mass spectrometry. J Proteome Res. 2015;14(8):3039–3050.
   PubMed Web of Science ®Google Scholar
• Partridge AH, Winer EP. On mammography–more agreement than disagreement. N Engl J Med. 2009;361(26):2499–2501.
   PubMed Web of Science ®Google Scholar
• Lee HB, Kang UB, Moon HG, et al. Development and validation of a novel plasma protein signature for breast cancer diagnosis by using multiple reaction monitoring-based mass spectrometry. Anticancer Res. 2015;35(11):6271–6279.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang M, Tomita T, et al. Selected reaction monitoring approach for validating peptide biomarkers. Proc Natl Acad Sci U S A. 2017;114(51):13519–13524.
   PubMed Web of Science ®Google Scholar
• Vegvari A, Sjodin K, Rezeli M, et al. Identification of a novel proteoform of prostate specific antigen (SNP-L132I) in clinical samples by multiple reaction monitoring. Mol Cell Proteomics. 2013;12(10):2761–2773.
   PubMed Web of Science ®Google Scholar
• Mohammed Y, van Vlijmen BJ, Yang J, et al. Multiplexed targeted proteomic assay to assess coagulation factor concentrations and thrombosis-associated cancer. Blood Adv. 2017;1(15):1080–1087.
   PubMed Web of Science ®Google Scholar
• Cui Z, Dewey S, Gomes AV. Cardioproteomics: advancing the discovery of signaling mechanisms involved in cardiovascular diseases. Am J Cardiovasc Dis. 2011;1(3):274–292.
   PubMedGoogle Scholar
• Mokou M, Lygirou V, Vlahou A, et al. Proteomics in cardiovascular disease: recent progress and clinical implication and implementation. Expert Rev Proteomics. 2017;14(2):117–136.
   PubMed Web of Science ®Google Scholar
• Chen SC, Huang JC, Su HM, et al. Prognostic cardiovascular markers in chronic kidney disease. Kidney Blood Press Res. 2018;43(4):1388–1407.
   PubMed Web of Science ®Google Scholar
• Luczak M, Formanowicz D, Marczak L, et al. Deeper insight into chronic kidney disease-related atherosclerosis: comparative proteomic studies of blood plasma using 2DE and mass spectrometry. J Transl Med. 2015;13:20.
   PubMed Web of Science ®Google Scholar
• Kristensen LP, Larsen MR, Mickley H, et al. Plasma proteome profiling of atherosclerotic disease manifestations reveals elevated levels of the cytoskeletal protein vinculin. J Proteomics. 2014;101:141–153.
   PubMed Web of Science ®Google Scholar
• Cheow ESH, Cheng WC, Yap T, et al. Myocardial injury is distinguished from stable angina by a set of candidate plasma biomarkers identified using iTRAQ/MRM-based approach. J Proteome Res. 2018;17(1):499–515.
   PubMed Web of Science ®Google Scholar
• Rezeli M, Vegvari A, Donnarumma F, et al. Development of an MRM assay panel with application to biobank samples from patients with myocardial infarction. J Proteomics. 2013;87:16–25.
   PubMed Web of Science ®Google Scholar
• Rezeli M, Sjodin K, Lindberg H, et al. Quantitation of 87 proteins by nLC-MRM/MS in human plasma: workflow for large-scale analysis of biobank samples. J Proteome Res. 2017;16(9):3242–3254.
   PubMed Web of Science ®Google Scholar
• Zhao C, Trudeau B, Xie H, et al. Epitope mapping and targeted quantitation of the cardiac biomarker troponin by SID-MRM mass spectrometry. Proteomics. 2014;14(11):1311–1321.
   PubMed Web of Science ®Google Scholar
• Mourino-Alvarez L, Baldan-Martin M, Gonzalez-Calero L, et al. Patients with calcific aortic stenosis exhibit systemic molecular evidence of ischemia, enhanced coagulation, oxidative stress and impaired cholesterol transport. Int J Cardiol. 2016;225:99–106.
   PubMed Web of Science ®Google Scholar
• Cohen Freue GV, Meredith A, Smith D, et al. Computational biomarker pipeline from discovery to clinical implementation: plasma proteomic biomarkers for cardiac transplantation. PLoS Comput Biol. 2013;9(4):e1002963.
   PubMed Web of Science ®Google Scholar
• Zhou B, Lu Y, Hajifathalian K, et al. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513–1530.
   PubMed Web of Science ®Google Scholar
• von Toerne C, Huth C, de Las Heras Gala T, et al. MASP1, THBS1, GPLD1 and ApoA-IV are novel biomarkers associated with prediabetes: the KORA F4 study. Diabetologia. 2016;59(9):1882–1892.
   PubMed Web of Science ®Google Scholar
• Bringans SD, Ito J, Stoll T, et al. Comprehensive mass spectrometry based biomarker discovery and validation platform as applied to diabetic kidney disease. EuPA Open Proteom. 2017;14:1–10.
   PubMedGoogle Scholar
• Kim K, Kim SJ, Han D, et al. Verification of multimarkers for detection of early stage diabetic retinopathy using multiple reaction monitoring. J Proteome Res. 2013;12(3):1078–1089.
   PubMed Web of Science ®Google Scholar
• Jin J, Min H, Kim SJ, et al. Development of diagnostic biomarkers for detecting diabetic retinopathy at early stages using quantitative proteomics. J Diabetes Res. 2016;2016:6571976.
   PubMedGoogle Scholar
• Sleddering MA, Markvoort AJ, Dharuri HK, et al. Proteomic analysis in type 2 diabetes patients before and after a very low calorie diet reveals potential disease state and intervention specific biomarkers. PLoS One. 2014;9(11):e112835.
   PubMed Web of Science ®Google Scholar
• Miyachi A, Murase T, Yamada Y, et al. Quantitative analytical method for determining the levels of gastric inhibitory polypeptides GIP1-42 and GIP3-42 in human plasma using LC-MS/MS/MS. J Proteome Res. 2013;12(6):2690–2699.
   PubMed Web of Science ®Google Scholar
• Kimzey MJ, Kinsky OR, Yassine HN, et al. Site specific modification of the human plasma proteome by methylglyoxal. Toxicol Appl Pharmacol. 2015;289(2):155–162.
   PubMed Web of Science ®Google Scholar
• Spiller S, Li Y, Bluher M, et al. Glycated lysine-141 in haptoglobin improves the diagnostic accuracy for type 2 diabetes mellitus in combination with glycated hemoglobin HbA1c and fasting plasma glucose. Clin Proteomics. 2017;14:10.
   PubMed Web of Science ®Google Scholar
• Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm (Vienna). 2017;124(8):901–905.
   PubMed Web of Science ®Google Scholar
• Pan C, Zhou Y, Dator R, et al. Targeted discovery and validation of plasma biomarkers of Parkinson’s disease. J Proteome Res. 2014;13(11):4535–4545.
   PubMed Web of Science ®Google Scholar
• Prince M, Bryce R, Albanese E, et al. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63–75 e2.
   PubMed Web of Science ®Google Scholar
• Li D, Huang F, Zhao Y, et al. Plasma lipoproteome in Alzheimer’s disease: a proof-of-concept study. Clin Proteomics. 2018;15:31.
   PubMed Web of Science ®Google Scholar
• Vos T, Allen C, Arora M, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388(10053):1545–1602.
   PubMed Web of Science ®Google Scholar
• Knochel C, Kniep J, Cooper JD, et al. Altered apolipoprotein C expression in association with cognition impairments and hippocampus volume in schizophrenia and bipolar disorder. Eur Arch Psychiatry Clin Neurosci. 2017;267(3):199–212.
   PubMed Web of Science ®Google Scholar
• Ritter SY, Collins J, Krastins B, et al. Mass spectrometry assays of plasma biomarkers to predict radiographic progression of knee osteoarthritis. Arthritis Res Ther. 2014;16(5):456.
   PubMed Web of Science ®Google Scholar
• Gibofsky A. Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. Am J Manag Care. 2012;18(13 Suppl):S295–302.
   PubMedGoogle Scholar
• Cabrales-Rico A, Ramos Y, Besada V, et al. Development and validation of a bioanalytical method based on LC-MS/MS analysis for the quantitation of CIGB-814 peptide in plasma from rheumatoid arthritis patients. J Pharm Biomed Anal. 2017;143:130–140.
   PubMed Web of Science ®Google Scholar
• Khan KS, Wojdyla D, Say L, et al. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;367(9516):1066–1074.
   PubMed Web of Science ®Google Scholar
• Blankley RT, Fisher C, Westwood M, et al. A label-free selected reaction monitoring workflow identifies a subset of pregnancy specific glycoproteins as potential predictive markers of early-onset pre-eclampsia. Mol Cell Proteomics. 2013;12(11):3148–3159.
   PubMed Web of Science ®Google Scholar
• Kim SM, Cho BK, Kang MJ, et al. Expression changes of proteins associated with the development of preeclampsia in maternal plasma: A case-control study. Proteomics. 2016;16(10):1581–1589.
   PubMed Web of Science ®Google Scholar
• Skov M, Hansen CR, Pressler T. Cystic fibrosis - an example of personalized and precision medicine. Apmis. 2019.
   PubMedGoogle Scholar
• Quon BS, Dai DL, Hollander Z, et al. Discovery of novel plasma protein biomarkers to predict imminent cystic fibrosis pulmonary exacerbations using multiple reaction monitoring mass spectrometry. Thorax. 2016;71(3):216–222.
   PubMed Web of Science ®Google Scholar
• Zhang P, Zhu M, Geng-Spyropoulos M, et al. A novel, multiplexed targeted mass spectrometry assay for quantification of complement factor H (CFH) variants and CFH-related proteins 1–5 in human plasma. Proteomics. 2017;17(6):1600237.
   Web of Science ®Google Scholar
• Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–16.
   PubMed Web of Science ®Google Scholar
• Chambers AG, Percy AJ, Simon R, et al. MRM for the verification of cancer biomarker proteins: recent applications to human plasma and serum. Expert Rev Proteomics. 2014;11(2):137–148.
   PubMed Web of Science ®Google Scholar
• Rai AJ, Gelfand CA, Haywood BC, et al. HUPO plasma proteome project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics. 2005;5(13):3262–3277.
   PubMed Web of Science ®Google Scholar
• Dupin M, Fortin T, Larue-Triolet A, et al. Impact of serum and plasma matrices on the titration of human inflammatory biomarkers using analytically validated SRM assays. J Proteome Res. 2016;15(8):2366–2378.
   PubMed Web of Science ®Google Scholar
• Domanski D, Percy AJ, Yang J, et al. MRM-based multiplexed quantitation of 67 putative cardiovascular disease biomarkers in human plasma. Proteomics. 2012;12(8):1222–1243.
   PubMed Web of Science ®Google Scholar
• Percy AJ, Chambers AG, Yang J, et al. Advances in multiplexed MRM-based protein biomarker quantitation toward clinical utility. Biochim Biophys Acta. 2014;1844(5):917–926.
   PubMed Web of Science ®Google Scholar
• Percy AJ, Byrns S, Pennington SR, et al. Clinical translation of MS-based, quantitative plasma proteomics: status, challenges, requirements, and potential. Expert Rev Proteomics. 2016;13(7):673–684.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Gallien S, El-Khoury V, et al. Quantification of SAA1 and SAA2 in lung cancer plasma using the isotype-specific PRM assays. Proteomics. 2015;15(18):3116–3125.
   PubMed Web of Science ®Google Scholar
• El-Khoury V, Beland M, Schritz A, et al. Identification of beta-arrestin-1 as a diagnostic biomarker in lung cancer. Br J Cancer. 2018;119(5):580–590.
   PubMed Web of Science ®Google Scholar
• Pontillo C, Filip S, Borras DM, et al. CE-MS-based proteomics in biomarker discovery and clinical application. Proteomics Clin Appl. 2015;9(3–4):322–334.
   PubMed Web of Science ®Google Scholar
• Sun L, Zhu G, Mou S, et al. Capillary zone electrophoresis-electrospray ionization-tandem mass spectrometry for quantitative parallel reaction monitoring of peptide abundance and single-shot proteomic analysis of a human cell line. J Chromatogr A. 2014;1359:303–308.
   PubMed Web of Science ®Google Scholar
• Abbatiello SE, Schilling B, Mani DR, et al. Large-scale interlaboratory study to develop, analytically validate and apply highly multiplexed, quantitative peptide assays to measure cancer-relevant proteins in plasma. Mol Cell Proteomics. 2015;14(9):2357–2374.
   PubMed Web of Science ®Google Scholar
• Mischak H, Allmaier G, Apweiler R, et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med. 2010;2(46):46ps42.
   PubMed Web of Science ®Google Scholar
• Ioannidis JPA, Bossuyt PMM. Waste, leaks, and failures in the biomarker pipeline. Clin Chem. 2017;63(5):963–972.
   PubMed Web of Science ®Google Scholar